3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Neoplasms
9
Carcinoma, Hepatocellular
5
Squamous Cell Carcinoma of Head and Neck
4
Melanoma
3
Colorectal Neoplasms
3
Recurrence
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Head and Neck Neoplasms
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Small Cell Lung Carcinoma
1
Sarcopenia
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Myositis
1
Metastatic Colorectal Adenocarcinoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Liver Neoplasms
1
Hyperthermia
1
Histiocytoma, Malignant Fibrous
1
Hematologic Neoplasms
1
Heart Diseases
1
Glioma
1
Eye Diseases
1
Esophageal Squamous Cell Carcinoma
1
Interventions
Sorafenib
42
Bevacizumab
16
Oxaliplatin
13
Radiosurgery
10
Gemcitabine
10
Doxorubicin
10
Capecitabine
10
Leucovorin
9
Hepatectomy
9
Fluorouracil
9
Cisplatin
9
Radiofrequency Ablation
8
Nivolumab
8
pembrolizumab
7
Drug Therapy
7
Carboplatin
7
Irinotecan
6
Cryosurgery
6
Talaporfin
5
Mitomycin
5
Everolimus
5
Erlotinib Hydrochloride
5
Electroporation
5
spartalizumab
4
Sunitinib
4
Melphalan
4
Ipilimumab
4
Epirubicin
4
Embolization, Therapeutic
4
regorafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Liver Neoplasms
×
Immune Checkpoint Inhibitors
×
Clear all
NCT03817736
2024-05-09
START-FIT
The University of Hong Kong
Phase 2
Completed
33 enrolled